Illumina, Inc. $ILMN Shares Bought by Amova Asset Management Americas Inc.

Amova Asset Management Americas Inc. grew its holdings in Illumina, Inc. (NASDAQ:ILMN) by 5.7% during the third quarter, HoldingsChannel.com reports. The fund owned 917,246 shares of the life sciences company’s stock after purchasing an additional 49,265 shares during the quarter. Amova Asset Management Americas Inc.’s holdings in Illumina were worth $87,028,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Loomis Sayles & Co. L P increased its holdings in Illumina by 1.9% in the 2nd quarter. Loomis Sayles & Co. L P now owns 4,225,529 shares of the life sciences company’s stock valued at $403,158,000 after purchasing an additional 78,317 shares in the last quarter. AQR Capital Management LLC lifted its stake in shares of Illumina by 55.3% during the second quarter. AQR Capital Management LLC now owns 3,295,880 shares of the life sciences company’s stock worth $313,290,000 after purchasing an additional 1,174,295 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Illumina by 0.7% in the second quarter. Geode Capital Management LLC now owns 2,869,187 shares of the life sciences company’s stock worth $272,921,000 after buying an additional 21,342 shares during the period. Bank of America Corp DE grew its stake in shares of Illumina by 1.9% in the second quarter. Bank of America Corp DE now owns 1,930,843 shares of the life sciences company’s stock valued at $184,222,000 after buying an additional 35,167 shares in the last quarter. Finally, ARK Investment Management LLC grew its stake in shares of Illumina by 25.7% in the third quarter. ARK Investment Management LLC now owns 1,467,879 shares of the life sciences company’s stock valued at $139,405,000 after buying an additional 299,801 shares in the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Insiders Place Their Bets

In other Illumina news, insider Scott M. Davies sold 323 shares of the business’s stock in a transaction on Friday, December 12th. The shares were sold at an average price of $136.09, for a total transaction of $43,957.07. Following the completion of the sale, the insider owned 17,887 shares in the company, valued at $2,434,241.83. The trade was a 1.77% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Patricia Leckman sold 2,370 shares of the stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $116.18, for a total transaction of $275,346.60. Following the sale, the senior vice president directly owned 16,321 shares in the company, valued at $1,896,173.78. This trade represents a 12.68% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders own 2.60% of the company’s stock.

Illumina Stock Down 0.5%

NASDAQ:ILMN opened at $128.97 on Thursday. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.72 and a current ratio of 2.08. The company has a market capitalization of $19.72 billion, a price-to-earnings ratio of 23.66, a price-to-earnings-growth ratio of 2.48 and a beta of 1.45. Illumina, Inc. has a one year low of $68.70 and a one year high of $155.53. The stock has a 50-day simple moving average of $134.74 and a 200 day simple moving average of $118.89.

Illumina (NASDAQ:ILMN) last released its earnings results on Thursday, February 5th. The life sciences company reported $1.35 EPS for the quarter, topping analysts’ consensus estimates of $1.26 by $0.09. The company had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.10 billion. Illumina had a return on equity of 31.04% and a net margin of 19.57%.Illumina’s quarterly revenue was up 5.0% compared to the same quarter last year. During the same quarter last year, the business posted $0.95 EPS. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. Sell-side analysts predict that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms recently commented on ILMN. Barclays boosted their price target on Illumina from $100.00 to $110.00 and gave the stock an “underweight” rating in a research report on Monday, December 15th. Weiss Ratings restated a “hold (c-)” rating on shares of Illumina in a research note on Monday, December 29th. Evercore set a $150.00 price target on shares of Illumina in a research note on Friday, February 6th. Guggenheim upped their price objective on shares of Illumina from $144.00 to $170.00 and gave the company a “buy” rating in a research report on Monday, January 26th. Finally, UBS Group reaffirmed a “neutral” rating and set a $135.00 target price on shares of Illumina in a research report on Friday, February 6th. Six analysts have rated the stock with a Buy rating, ten have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, Illumina has a consensus rating of “Hold” and an average price target of $129.69.

Illumina Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.